5 Best Biotech ETFs for 2026 and How to Invest


Biotech ETFs (exchange-traded funds) hold the stocks of companies in the biotech sector. Hundreds of biotech companies are hard at work developing innovative therapies. Some could even be game changers in preventing and treating diseases.

Want to invest in an exciting and fast-growing sector? You could buy individual biotech stocks. The downside of that, though, is that many of stocks are very risky. Biotech ETFs offer an easier way to invest in the sector by lowering your risk and portfolio volatility.

Five top biotech ETFs for 2026

The best biotech ETFs tend to be the biggest ones. They have a lot of assets under management and relatively low expense ratios. Here are five of the best biotech ETFs.

Data as of Nov 18, 2026. Showing 5 of 5 total entries.

1. iShares Biotechnology ETF

IBB iShares Trust – iShares Biotechnology ETF

$206.92-$0.05 (-0.02%)

NASDAQ · As of 12:24 PM ET 11/18/26

  • Total assets: $10.3 billion
  • Expense ratio: 0.44%
  • Dividend yield: 0.2%

The iShares Biotechnology ETF (IBB -0.02%) seeks to track an index of all U.S.-listed biotechnology stocks. The ETF held over 240 biotech stocks in September 2026.

Among the iShares Biotechnology ETF’s top holdings are some of the largest biotech stocks by market capitalization. They include:

  • Vertex Pharmaceuticals (VRTX +0.47%)
  • Amgen (AMGN -2.11%)
  • Gilead Sciences (GILD -0.42%)
  • Regeneron Pharmaceuticals (REGN -0.47%)
  • Argenx (ARGX -0.25%)

Since its inception in 2001, the ETF has delivered an average annualized total return of 7.29%. Over the past five years, it has generated an annualized total return of 3.31%.

2. State Street SPDR S&P Biotech ETF

XBI SPDR Series Trust – SPDR S&P Biotech ETF

$146.01+$0.73 (+0.50%)

NYSEMKT · As of 12:20 PM ET 11/18/26

  • Total assets: $10.6 billion
  • Expense ratio: 0.35%
  • Dividend yield: 0.36%

The State Street SPDR S&P Biotech ETF (XBI +0.86%) seeks to track the S&P Biotechnology Select Industry Index. The index uses a modified equal weighting, meaning each stock’s share of total assets is roughly the same. It gives investors exposure to large-, mid-, and small-cap biotech stocks. 

The ETF currently owns more than 150 stocks. Its top holdings include:

  • Moderna (MRNA -1.14%)
  • Twist Bioscience (TWST +5.29%)
  • Halozyme Therapeutics (HALO +1.00%)
  • Natera (NTRA -1.03%)
  • Kymera Therapeutics (KYMR +0.45%)

However, because of its modified equal weighting, none of the ETF’s largest positions account for a significantly greater percentage of assets than other stocks.  

The SPDR S&P Biotech ETF has delivered an annualized total return of 12% since its inception in 2006. Over the past five years, however, the fund generated an average annual return of only 4.23%.

3. Ark Genomic Revolution ETF

ARKG Ark ETF Trust – Ark Genomic Revolution ETF

$41.73+$1.23 (+3.04%)

NYSEMKT · As of 12:24 PM ET 11/18/26

  • Total assets: $1.6 billion
  • Expense ratio: 0.75%
  • Dividend yield: 0%

The Ark Genomic Revolution ETF (ARKG +2.69%) is one of several exchange-traded funds operated by Cathie Wood’s Ark Invest. The fund invests in the stocks of companies that incorporate genomics into their businesses. It focuses on gene-editing, molecular diagnostics, and virtual care stocks, as well as companies developing targeted therapeutics. 

The ETF typically owns between 40 and 60 stocks. Its top positions as of September 2026 include:

  • 10x Genomics (TXG +1.42%)
  • Twist Bioscience
  • Tempus AI (TEM +0.55%)
  • CRISPR Therapeutics (CRSP +4.20%)
  • Personalis (PSNL +1.35%)

The Ark Genomic Revolution ETF began trading in 2014. As of September 2026, it had generated an average annual return of around 8.25%. Over the past five years, the ETF’s annualized return has been -11.12%.

4. First Trust NYSE Arca Biotechnology Index Fund

FBT First Trust Exchange-Traded Fund – First Trust Nyse Arca Biotechnology Index Fund

$268.50+$1.64 (+0.61%)

NYSEMKT · As of 12:21 PM ET 11/18/26

  • Total assets: $2.9 billion
  • Expense ratio: 0.55%
  • Dividend yield: 0%

The First Trust NYSE Arca Biotechnology Index Fund (FBT +0.61%) seeks to track the performance of the NYSE Arca Biotechnology Index. The index holds equal weights in a cross-section of biotech companies, including those focused on genomics and the development of monoclonal antibody-based technologies.

Since its inception in 2006, the ETF has achieved an average annual total return of 13.81%. Over the past five years, the fund generated an annualized return of 9.14%.

  • Halozyme Therapeutics
  • Corcept Therapeutics (CORT -2.68%)
  • Neogenomics (NEO +1.25%)
  • Natera
  • Regeneron Pharmaceuticals (REGN -0.47%)

Since its inception in 2006, the ETF has achieved an average annual total return of 13.8%. Over the past five years, the fund generated an annualized return of 9.14%.

5. VanEck Biotech ETF

BBH VanEck ETF Trust – VanEck Biotech ETF

$246.40-$1.38 (-0.56%)

NASDAQ · As of 12:21 PM ET 11/18/26

  • Total assets: $459 million
  • Expense ratio: 0.35%
  • Dividend yield: 0.42%

The VanEck Biotech ETF (BBH -0.56%) seeks to own the most liquid biotech companies, as measured by market cap and trading volume. As such, its approach tends to favor the biggest companies in the biotech sector. The ETF’s portfolio can include U.S. and foreign companies listed on U.S. stock exchanges.

The ETF owned 25 biotech stocks in September 2026. Its top holdings include:

  • Amgen
  • Gilead Sciences
  • Vertex Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Moderna

The VanEck Biotech ETF was launched on Dec. 20, 2011. Since then, the fund has generated an annualized total return of about 14.20%. Over the past five years, the ETF’s average annual return was only 2.29%.

How to buy biotech ETFs

  1. Open your brokerage account: Log in to your brokerage account where you handle your investments. If you don’t have one yet, take a look at our favorite brokers and trading platforms to find the right one for you.
  2. Search for the biotech ETF: Enter the ticker into the search bar to bring up the ETF’s trading page.
  3. Decide how many shares to buy: Consider your investment goals and how much of your portfolio you want to allocate to this ETF.
  4. Select order type: Choose between a market order to buy at the current price or a limit order to specify the maximum price you’re willing to pay.
  5. Submit your order: Confirm the details and submit your buy order.
  6. Review your purchase: Check your portfolio to ensure your order was filled as expected and adjust your investment strategy accordingly.

Benefits and risks of investing in biotech ETFs

The benefits of investing in biotech ETFs include:

  • Diversification: Biotech ETFs own many biotech stocks. This reduces the risk of one big loser dragging down your returns.
  • Professional management: The biotech industry is complicated. Investing in biotech ETFs gives you access to professional managers who know the industry well.
  • Liquidity: Some individual biotech stocks aren’t heavily traded. To sell these stocks quickly, you might have to accept a lower price. The larger biotech ETFs allow you to avoid this liquidity risk.

However, there are also several potential risks associated with investing in biotech ETFs, such as:

  • Overexposure to one sector: If you invest too heavily in biotech ETFs, your overall returns could be lower during periods when biotech stocks are out of favor.
  • Volatility: Biotech ETFs can be highly volatile because biotech stocks are often highly volatile.
  • Less control: Biotech ETFs could own biotech stocks that you don’t like. Buying these funds reduces your control over your investments.

Methodology: How these ETFs were chosen

The most important criterion in selecting these five ETFs was that they all held a significant number of individual biotech stocks. Most of them clearly reflect their focus on the biotech industry with their names.

Another key factor in choosing the funds was their liquidity (i.e., how easily they can be traded without significantly affecting their price). Each of these biotech ETFs is highly liquid.

Each fund’s net assets under management amount was another consideration. Most of these ETFs have AUMs in the billions, with one outlier — the Van Eck Biotech ETF.

Should you invest in biotech ETFs?

Investors with a low tolerance for risk and volatility probably shouldn’t invest in biotech ETFs. Like the individual biotech stocks they own, biotech ETFs can be highly volatile. Income investors will also likely find better alternatives since the dividend yields of biotech ETFs tend to be low (or nonexistent).

On the other hand, more aggressive investors with high risk tolerances could find biotech ETFs quite appealing. They offer a convenient way to invest in a basket of biotech stocks in one fell swoop. Over the long term, biotech ETFs could generate market-beating returns.

Related investing articles

Biotech ETFs FAQ

Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Alkermes Plc, Alnylam Pharmaceuticals, Amgen, CRISPR Therapeutics, Corcept Therapeutics, Gilead Sciences, Guardant Health, Iqvia Holdings, Krystal Biotech, Mirum Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Twist Bioscience, and Vertex Pharmaceuticals. The Motley Fool recommends BioNTech Se and SPDR Series Trust – SPDR S&P Biotech ETF. The Motley Fool has a disclosure policy.

Leave a Reply

Your email address will not be published. Required fields are marked *